As of Q4 2024, the wholesale acquisition cost of autoimmune disease drug Remicade was 1,168 U.S. dollars, compared to 946 U.S. dollars for the biosimilar Inflectra. Biosmilars of Remicade were able to reduce costs between 19 and 59 percent. This statistic illustrates a comparison WAC of Remicade vs biosimilars in the United States.
Comparison of the wholesale acquisition cost (WAC) of Remicade vs biosimilars in the United States as of Q4 2024
(in U.S. dollars)
Characteristic
Wholesale acquisition cost in U.S. dollars
Remicade
1,168
Inflectra
946
Renflexis
753
Avsola
500
Infliximab (unbranded)*
475
Created with Highcharts 7.2.2Wholesale acquisition cost in U.S. dollars1,1681,168946946753753500500475475RemicadeInflectraRenflexisAvsolaInfliximab (unbranded)*
02505007501,0001,2501,500
Add this content to your personal favorites. These can be accessed from the favorites menu in the main navigation.
You have no right to use this feature.
Make sure to contact us if you are interested in scientific citation.
You can upgrade your account to enable this functionality for all statistics.
This feature is not available with your current account.Request access
Learn more about how Statista can support your business.
Samsung Bioepis. (November 10, 2024). Comparison of the wholesale acquisition cost (WAC) of Remicade vs biosimilars in the United States as of Q4 2024 (in U.S. dollars) [Graph]. In Statista. Retrieved February 19, 2025, from https://www.statista.com/statistics/1186621/comparison-wac-remicade-vs-biosimilars-us/
Samsung Bioepis. "Comparison of the wholesale acquisition cost (WAC) of Remicade vs biosimilars in the United States as of Q4 2024 (in U.S. dollars)." Chart. November 10, 2024. Statista. Accessed February 19, 2025. https://www.statista.com/statistics/1186621/comparison-wac-remicade-vs-biosimilars-us/
Samsung Bioepis. (2024). Comparison of the wholesale acquisition cost (WAC) of Remicade vs biosimilars in the United States as of Q4 2024 (in U.S. dollars). Statista. Statista Inc.. Accessed: February 19, 2025. https://www.statista.com/statistics/1186621/comparison-wac-remicade-vs-biosimilars-us/
Samsung Bioepis. "Comparison of The Wholesale Acquisition Cost (Wac) of Remicade Vs Biosimilars in The United States as of Q4 2024 (in U.S. Dollars)." Statista, Statista Inc., 10 Nov 2024, https://www.statista.com/statistics/1186621/comparison-wac-remicade-vs-biosimilars-us/
Samsung Bioepis, Comparison of the wholesale acquisition cost (WAC) of Remicade vs biosimilars in the United States as of Q4 2024 (in U.S. dollars) Statista, https://www.statista.com/statistics/1186621/comparison-wac-remicade-vs-biosimilars-us/ (last visited February 19, 2025)
Comparison of the wholesale acquisition cost (WAC) of Remicade vs biosimilars in the United States as of Q4 2024 (in U.S. dollars) [Graph], Samsung Bioepis, November 10, 2024. [Online]. Available: https://www.statista.com/statistics/1186621/comparison-wac-remicade-vs-biosimilars-us/
Profit from additional features with an Employee Account
Please create an employee account to be able to mark statistics as favorites.
Then you can access your favorite statistics via the star in the header.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.